Weill Cornell Pooled genetic screens to identify factors promoting aberrant EEC proliferation Medicine Sanlan Li¹, Xiaofeng Steve Huang¹, Wei Gu¹, Ramesh Shivdasani², Joe Q. Zhou¹ ¹Department of Medicine, Weill Cornell Medicine; ²Dana-Farber Cancer Institute, Harvard Medical School

INTRODUCTION

Carcinoid tumors exhibit features of advanced cytodifferentiation and our comparison of carcinoid tumors with normal human enteroendocrine cell (EEC) transcriptomes and epigenomes (Accelerator project – Zhou & Shivdasani) affirms that carcinoid tumors are indeed arrested late in the EEC differentiation trajectory. Normal mature enteroendocrine cells (EECs), however, do not proliferate. Thus, a simple hypothesis for carcinoid formation is that aberrant gene regulation during EEC differentiation prevent cell cycle exit and enables continued proliferation, sowing the seeds for carcinoid tumorigenesis. We designed gain- (cDNA) and loss-of-function (CRISPR) screens using normal human EECs to identify causal factors that promote aberrant, continued EEC proliferation.



Schematic illustration of gain-of-function screen using hORFeome library (A) or loss-of-function screen using epigenetic sgRNA CRISPR library (B). Human ileal stem cells were engineered for inducible expression of NGN3, puromycin, and mCherry for EEC induction and labeling.



A. Representative images showing 2D cultured ileal stem cell colonies with inducible NGN3 expression and EEC cells generated after 4-hydroxy tamoxifen (4-HT) application; B, C. Immunostaining of EECs and quantification. Scale bars : 100 µm in A and 25 µm in **B.** Note the lack of stem cell marker LGR5 and rostral intestinal EECs including GIP, Ghrelin, and CCK.



B. Diagram showing hORFeome plasmid; C. Immunostaining showing V5 epitope-tag expression in hEECs that integrated hORFeome lentivirus. hORFs are tagged with V5. Arrows indicate mCherry⁺V5⁺CHGA⁺ cells. The percentage of V5⁺mCherry⁺ cells relative to mCherry⁺ cells was approximately 60%. Scale bars: 50 μm.





FACS purification of EdU⁺CHGA⁺ cells • At the same time, we will perform a CRISPR/Cas9 screen with a epigenetic target library (~500 genes).